AstraZeneca has drawn up plans to break out its China business and list it separately in Hong Kong as a way to shelter the company against mounting geopolitical tensions. ( read original story ...)
AstraZeneca planning China business spin off -FT
Drugmaker AstraZeneca is drafting a plan to spin off its China business, and listing a separate unit in Hong Kong is being viewed as an option, the Financial Times reported on Sunday. ( read original story ...)
Syngenta’s $9bn IPO approved by Shanghai Exchange
Agrichemical supplier Syngenta Group Friday received Friday the go-ahead to list on the Shanghai Stock Exchange, with the aim of raising 65 billion yuan ($9.1 billion) in what would be the one of ... ( read original story ...)
Is doing business in China becoming impossible for foreigners?
The space for foreigners doing business in China was already being constrained by restrictions that their own governments, led by America’s, have placed on Chinese companies amid rising geopolitical ... ( read original story ...)
Top American CEOs Are Quietly Jet Setting To China To Reforge Business Ties As US Relations Sour
Some of America’s top CEOs have traveled to China recently, emphasizing the need for cooperation between the countries and engaging with Chinese Communist Party (CCP) officials on secret trips. ( read original story ...)
Shanghai stock exchange to review Syngenta IPO application on June 16
The Shanghai stock exchange will review Swiss agrichemicals and seeds group Syngenta's application for listing on its main board on June 16, a filing posted on the exchange showed on Friday. Last ... ( read original story ...)
U.S. Business Interest In China Is Slowly Recovering, Ex-American Diplomat Says
Strained relations between Washington and Beijing appear to be stabilizing, a shift that is stirring renewed business interest in China among U.S. companies, a former long-term U.S. diplomat who is ... ( read original story ...)